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primary site of TFPI production,8 and 50% to 80% of
TFPI in vivo is contained within endothelial cells.9
Plasma TFPI levels in vivo increase 15 minutes to
1 hour after heparin injection,10-12 presumably due to
a heparin-dependent release of TFPI from endothe-
lial cells. However, in vitro studies investigating the
heparin-stimulated release of TFPI from endothelial
cells have yielded conflicting results. Studies using
primary and immortalized endothelial cells have
demonstrated a significant release in TFPI 15 minutes
to 1 hour after heparin stimulation,13-16 although
other reports suggest no significant increase occurs
until 24 hours.17,18
Recent evidence indicates that there are 2 iso-
forms of TFPI in endothelial cells, TFPIα and TFPIβ
(Figure 1A).20 Most TFPIα is intracellular and is
released by heparin,16,21 which increases the antico-
agulant potential of the surrounding environment
(Figure 1B). A small amount of TFPIα is anchored
indirectly to the cell surface, presumably to a glyco-
sylphosphatidylinositol-lipid (GPI)−anchored protein.20
Blood coagulation is a complex series of reac-tions that prevent blood loss after vascularinjury. This process is initiated by the release
of tissue factor to the circulating blood. Tissue fac-
tor forms a complex with factor VII (FVII), which
activates factor X (FX), and ultimately leads to fibrin
formation. This trigger of coagulation is tightly reg-
ulated by tissue factor pathway inhibitor (TFPI), a
trivalent Kunitz-type protease inhibitor of FXa and
TF-FVIIa.1,2
Tissue factor pathway inhibitor is heterogeneous
in size,3 with the 43 kDa form possessing the great-
est anticoagulant activity.4-7 The endothelium is the
The release of tissue factor pathway inhibitor (TFPI)
from human umbilical vein endothelial cells (HUVECs)
was investigated using heparin and phospholipase C. The
experiment included incubating HUVECs with 0, 1, or
10 U/mL heparin diluted in Dulbecco Modified Eagle’s
Medium plus 5% fetal calf serum for 1 or 24 hours. A sta-
tistically significant increase in TFPI activity levels was
seen at 1 hour, but not at 24 hours. A 20-fold increase in
the release of TFPI after phospholipase C treatment of
HUVECs was demonstrated, confirming that it is glyco-
sylphosphatidylinositol-lipid (GPI) anchored. Sequential
treatment of HUVECs with phospholipase C and
heparin was performed, and a trend was observed where
GPI-anchored TFPI levels were increased after 1 hour of
pretreatment with heparin but were decreased after 24
hours. Serum is a requirement for the heparin-dependent
release of TFPI from HUVECs. Heparin pretreatment of
HUVECs may affect levels of GPI anchored TFPI in a
time and dose-dependent manner.
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Approximately 75% of cell-surface-bound TFPIα
is released by phosphatidylinositol-specific phospho-
lipase C (PLC; Figure 1C), with the remainder
released by sequential PLC then heparin treatment
(Figure 1D).20 Tissue factor pathway inhibitor-β is an
alternate splice variant of the TFPI gene that lacks
the third Kunitz domain and C-terminus of TFPIα.
It is anchored directly to the endothelial cell surface
by a GPI anchor20 and is released entirely by PLC in
vitro (Figure 1C).20
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Figure 1. This illustration depicts the different pools of tissue factor pathway inhibitor (TFPI) within endothelial cells and their
release after cell treatments. A: Tissue factor pathway inhibitor-α (TFPIα) is present intracellularly and also on the cell
surface bound to a glycosylphosphatidylinositol-lipid–anchored protein. B: The intracellular pool is released by heparin,
whereas (C) 75% of the cell surface pool is released by phospholipase C (PLC). D: The remaining 25% is released by
PLC then heparin treatment. Tissue factor pathway inhibitor-β (TFPIβ) is present on the cell surface, (A) bound directly
by a GPI anchor and (C) released by PLC. Adapted from Lindahl AK, Abildgaard U, Stokke G. Release of extrinsic path-
way inhibitor after heparin injection: increased response in cancer patients. Circulation. 2003;108:623-627.
The aims of this study were to:
1. validate the conditions required to demonstrate the
heparin-dependent release of TFPI from human
umbilical vein endothelial cells (HUVECs);
2. determine the effect of PLC on heparin-
releasable TFPI in HUVECs, and




Factor VII was purchased from Enzyme Research
Laboratories (South Bend, Ind). Factor X was pur-
chased from Sigma Chemical Company (St Louis, Mo).
Innovin was from Dade Behring (Marburg, Germany).
S-2222, a chromogenic substrate specific for FXa, was
obtained from Chromogenix (Milano, Italy).
Tissue culture flasks (25 cm2) were purchased
from Orange Scientific (Braine-l’Alleud, Belgium)
and 35-mm culture dishes from Becton Dickinson
(Franklin Lakes, NJ). All culture media components
(fetal calf serum, penicillin/streptomycin, ampho-
tericin B, L-glutamine, sodium bicarbonate) and
culture reagents (trypsin/ethylenediaminetetraacetic
acid, Hanks Balanced Salt Solution, and Dulbecco
Modified Eagle’s Medium [DMEM]) were pur-
chased from TRACE Scientific (Noble Park, VIC,
Australia), and MCDB 131 culture media was pur-
chased from Invitrogen (Mulgrave, VIC, Australia).
Unfractionated heparin (UFH) and low-molecular-
weight heparin (LMWH; Fragmin) were from Pharmacia
and Upjohn (Peapack, NJ). Phosphatidylinositol-
specific PLC (P-6466) was purchased from Invitrogen.
Albumin (Albumex) was from CSL (Parkville, Victoria,
Australia). All laboratory grade reagents were from
Merck (Kilsyth, Victoria, Australia), Sigma Chemical




Ethics approval for umbilical cord collection for this
study was obtained from the Human Research
Ethics Committee, Curtin University of Technology
(Approval No HR 62/2002) and the North
Metropolitan Health Services Board. Informed writ-
ten consent was obtained from all participants in the
study before collection.
Cell Culture
A previously published method was used to isolate
HUVECs from umbilical cords.22 Cells were grown
in 1% gelatin-coated 25 cm2 tissue culture flasks at
37°C in 5% carbon dioxide. The culture medium
consisted of MCDB 131 basal medium, 15% fetal
calf serum (FCS), 100 μg/mL streptomycin, 100
U/mL penicillin, 2.5 μg/mL amphotericin B, 4 mM
L-glutamine, and 2.2% sodium bicarbonate.
Once confluent, cells were passaged using
0.05% trypsin/0.025% EDTA and seeded into 1%
gelatin-coated 35-mm tissue culture dishes at a den-
sity of approximately 10 000 cells/cm2. They were
grown to confluence in DMEM basal medium, 15%
FCS, 100 μg/mL streptomycin, 100 U/mL penicillin,
2.5 μg/mL amphotericin B, 4 mM L-glutamine, and
2.2% sodium bicarbonate.
Heparin Stimulation of HUVECs
Once confluence was achieved, the culture medium
was removed and replaced with DMEM containing
5% FCS, and the cells were incubated for 24 hours.
This medium was removed and the cells washed twice
with phenol-red free Hanks Balanced Salt Solution
(HBSS). To this was added 1 mL of heparin at a con-
centration of 0 (control), 1, or 10 U/mL (diluted in
either phenol red free DMEM or phenol red free
DMEM containing 5% FCS), and the cells were incu-
bated at 37°C for 1 hour or 24 hours. The super-
natants were collected and assayed for TFPI activity.
Phospholipase C Treatment of HUVECs
After the HUVECs grew to confluence, the medium
was removed, and the cells were serum starved in
5% FCS for 24 hours. This medium was removed,
and the cells were washed twice with Tris-buffered
saline (TBS; 50 mM Tris, 150 mM sodium chloride,
pH 7.4) and incubated with 0.5 mL of 0.4 U/mL
PLC (diluted in TBS) or TBS (control) for 2 hours
at 37°C. The supernatants were collected and
assayed for TFPI activity.
Heparin, Then Phospholipase C
Treatment of HUVECs
Once the HUVECs had grown to confluence, the
growth medium was removed, and the cells were
serum starved (in 5% FCS) for 24 hours. This medium
was removed, and the cells were washed twice with
HBSS and incubated with 1 mL of heparin (0, 1, or
Release of TFPI From Endothelial Cells / Ellery et al 269
10 U/mL; diluted in phenol red free DMEM con-
taining 5% FCS) at 37°C for 1 hour or 24 hours,
after which the supernatants were collected. The
cells were washed twice in TBS and incubated with
0.5 mLs of 0.4 U/mL PLC (diluted in TBS) or TBS
(control) for 2 hours at 37°C. The supernatants
were collected and assayed for TFPI activity.
Phospholipase C, Then Heparin
Treatment of HUVECs
The HUVECs were grown to confluence as previ-
ously stated. The growth medium was removed, and
the cells were serum starved (in 5% FCS) for 24
hours. This medium was removed, and the cells
were washed twice in TBS. The cells were incubated
with 0.5 mL of 0.4 U/mL PLC (diluted in TBS) or
TBS (control) for 2 hours at 37°C, after which the
supernatants were collected. The cells were washed
twice with HBSS and incubated with 1 mL of
heparin (0, 1, or 10 U/mL; diluted in phenol red free
DMEM containing 5% FCS) at 37°C for 1 hour or
24 hours. The supernatants were collected and all
supernatants were assayed for TFPI activity.
Tissue Factor Pathway
Inhibitor Activity Assay
The TFPI activity assay was based on a previously
published method,23 with slight modifications as
previously published.24-27 Briefly, 25 μL of the test
sample (pooled normal plasma or endothelial cell
supernatant) was incubated with 100 μL of a reac-
tion mixture (containing final concentrations of
0.005 U/mL FX, 0.0075 U/mL FVII, 18.75 mM cal-
cium chloride and 1/160 Innovin) at 37°C for
20 minutes. Then 50 μL of a 0.2 U/mL FX and 1.0 mM
S-2222 mixture was added and incubated at 37°C
for 30 minutes. The reaction was stopped with 50 μL
of 50% acetic acid, and the absorbance was read at
405 nm using a Labsystems Multiskan Ascent plate
reader (Thermo Scientific, Waltham, Mass).
Samples were compared with a standard curve
to determine TFPI activity. The standard curve was
generated using dilutions of pooled normal plasma
(neat to 1/128) obtained from 20 healthy male donors
and designated to contain 1 U/mL TFPI. All samples
were heated for 15 minutes at 56°C, placed on ice
for 2 minutes, and then centrifuged at 1500g for 15
minutes before assay to remove FVII, FX, and fib-
rinogen. All dilutions were made in a modified TBS
(50 mM Tris, 150 mM sodium chloride, 10 mM
trisodium citrate, 2 mg/mL albumin, and 2 μg/mL
Polybrene, pH 8.0). The intraassay and interassay coef-
ficients of variation were 1.7% and 5.0%, respectively.
Statistical Analysis
Statistical analysis was performed using GraphPad
Prism 4 (GraphPad Software, San Diego, Calif). Results
are reported as the mean of at least 2 experiments
and were compared using the 1-way analysis of vari-
ance (ANOVA). Two-way ANOVA was used for the
heparin/PLC experiments. A value of P < .05 was
considered to be statistically significant.
Results
Assessment of Heparin-Releasable TFPI
in the Absence of 5% FCS
The activity levels of TFPI in the HUVEC super-
natants after 1 hour of incubation with 0, 1, or
10 U/mL UFH diluted in DMEM were 8.0, 6.5,
and 10.0 mU/mL, respectively (Figure 2A). After
24 hours, TFPI activity levels were 101.5, 124.5,
and 104.2 mU/mL using 0, 1, or 10 U/mL UFH
(Figure 2B). No significant increase in TPFI activity
was observed using 1 or 10 U/mL of UFH at 1 hour
(P > .05) or 24 hours (P > .05) compared with the
0 U/mL control.
Tissue factor pathway inhibitor activity levels in
HUVEC supernatants after 1 hour of incubation
with 0, 1, or 10 U/mL LMWH diluted in DMEM were
7.5, 8.9, and 12.5 mU/mL, respectively (Figure 3A).
After 24 hours, TFPI activity levels were 97.9, 118.4,
and 151.7 mU/mL using 0, 1, or 10 U/mL LMWH
(Figure 3B). There were increases in TFPI activity at
1 hour and 24 hours using LMWH, although these
were not statistically significant (P > .05 for both
time points).
Assessment of Heparin Releasable TFPI
in the Presence of 5% FCS
Tissue factor pathway inhibitor activity levels in
HUVEC supernatants after 1 hour incubation with
0, 1, or 10 U/mL UFH diluted in DMEM plus 5%
FCS were 9.0, 18.3, and 18.4 mU/mL, respectively
(Figure 4A). After 24 hours, TFPI activity levels
were 93.6, 131.8, and 121.2 mU/mL using 0, 1, and
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10 U/mL UFH (Figure 4B). A statistically significant
increase in TFPI activity among all UFH concentra-
tions was observed at 1 hour (P < .0001) but not at
24 hours (P > .05).
Tissue factor pathway inhibitor activity levels in
HUVEC supernatants after 1 hour incubation with
0, 1, or 10 U/mL LMWH diluted in DMEM plus 5%
FCS were 8.8, 13.28, and 21.37 mU/mL, respec-
tively (Figure 5A). After 24 hours, TFPI levels were
100.3, 115.2, and 137.7 mU/mL using 0, 1, and 10
U/mL LMWH (Figure 5B). A statistically significant
increase in TFPI activity between all LMWH con-
centrations was observed at 1 hour (P < .05) but not
at 24 hours (P > .05).
Assessment of the Release of GPI-
Anchored TFPI
As shown in Figure 6, treatment of HUVECs with
PLC resulted in a significantly greater release of
TFPI compared with control (16.87 mU/mL versus
0.68 mU/mL, P < .0001).
Assessment of Heparin-Releasable
TFPIα After Phospholipase C Treatment
of Endothelial Cells
Heparin-releasable TFPI activity levels in HUVEC
supernatants after 1 hour of UFH exposure (0, 1, or
10 U/mL) were 2.23, 7.01, and 7.01 mU/mL in control
cells and 4.58, 6.03, and 8.68 mU/mL in PLC-treated
cells, respectively (Figure 7A). Heparin-releasable
TFPI activity levels in HUVEC supernatants after
24 hours’ UFH treatment (0, 1, or 10 U/mL) were
75.49, 102.12, and 100.48 mU/mL in control cells
and 79.90, 96.07, and 90.66 mU/mL in PLC-treated
cells, respectively (Figure 7B). There was no statisti-
cally significant difference between PLC-treated
and control cells in heparin-releasable TFPI activity
levels after subsequent treatment with UFH after
1 hour (P > .05) or 24 hours (P > .05).
Heparin-releasable TFPI activity levels in HUVEC
supernatants after 1 hour of LMWH treatment (0, 1,
or, 10 U/mL) were 2.95, 3.83, and 3.98 mU/mL in
control cells and 4.29, 3.10, and 4.34 mU/mL
in PLC-treated cells, respectively (Figure 8A).
Heparin-releasable TFPI activity levels in HUVEC
supernatants after 24 hours’ LMWH treatment
(0, 1, or 10 U/mL) were 38.22, 45.88, and 46.17
mU/mL in control cells and 29.68, 37.44, and 43.54
mU/mL in PLC-treated cells, respectively (Figure
8B). There was no statistically significant difference
between PLC-treated and control cells in heparin-
releasable TFPI activity levels after subsequent
treatment with LMWH after 1 hour (P > .05) or
24 hours (P > .05).
Assessment of GPI-Anchored
TFPI After Heparin Treatment of
Endothelial Cells
Glycosylphosphatidylinositol-lipid−anchored TFPI
activity levels in HUVEC supernatants of cells
treated for 1 hour with UFH (0, 1, and 10 U/mL)
were 13.09, 14.71, and 15.58 mU/mL, respectively
(Figure 9A), and after 24 hours of treatment with
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Figure 2. Effect of unfractionated heparin (UFH) on the release
of tissue factor pathway inhibitor (TFPI) from human
umbilical vein endothelial cells is shown. Cells were
stimulated with unfractionated heparin (UFH), diluted
in Dulbecco Modified Eagle’s Medium only, for (A)
1 hour or (B) 24 hours. Columns represent mean
heparin-releasable TFPI activity (mU/mL), and the
error bars show 1 standard deviation.
UFH (0, 1 and 10 U/mL) were 11.43, 8.53 and 9.63
mU/mL, respectively (Figure 9, B). Although there
was no statistically significant difference in GPI-
anchored TFPI levels in HUVECs that were treated
with different UFH concentrations for 1 hour (P >
.05) or 24 hours (P > .05), there was a trend where
GPI-anchored levels were increased by UFH pre-
treatment after 1 hour and decreased after 24 hours.
Glycosylphosphatidylinositol-lipid−anchored
activity levels in HUVEC supernatants of cells
treated for 1 hour with LMWH (0, 1 and 10 U/mL)
were 19.49, 20.90, and 24.54 mU/mL, respectively
(Figure 10A), and for 24 hours with LMWH
(0, 1, and 10 U/mL) were 24.29, 15.84, and 16.94
mU/mL, respectively (Figure 10B). Although there
was no statistically significant difference in GPI-
anchored TFPI levels in HUVECs that were treated
with different LMWH concentrations for 1 hour
(P > .05) or 24 hours (P > .05), there was a trend
where GPI-anchored levels were increased by
272 Clinical and Applied Thrombosis/Hemostasis / Vol. 14, No. 3, July 2008
Figure 4. Effect of unfractionated heparin (UFH) on the release of tissue factor pathway inhibitor (TFPI) from human umbilical
vein endothelial cells. Cells were stimulated with UFH (diluted in Dulbecco Modified Eagle’s Medium plus 5% fetal calf
serum) for (A) 1 hour or (B) 24 hours. Columns represent mean heparin-releasable TFPI activity (mU/mL), and error bars
show 1 standard deviation. **Represents a statistically significant result.
Figure 3. Effect of low-molecular-weight heparin (LMWH) on the release of tissue factor pathway inhibitor (TFPI) from human
umbilical vein endothelial cells. Cells were stimulated with LMWH (diluted in Dulbecco Modified Eagle’s Medium only) for
(A) 1 hour or (B) 24 hours. Columns represent mean heparin-releasable TFPI activity (mU/mL), and the error bars show 1
standard deviation.
LMWH treatment after 1 hour and decreased after
24 hours.
Discussion
Tissue factor pathway inhibitor is an important
hemostatic regulator that contributes to the antico-
agulant effect of heparins. The full-length form
(43 kDa) has the greatest anticoagulant activity,4 is
released from endothelial cells in response to UFH
and LMWH,13,15,16 and is thus termed heparin-
releasable TFPI. Previous investigations suggest that
this is TFPIα.21 Studies on the effect of heparins on
TFPI release from endothelial cells in vitro have
demonstrated conflicting results,13-18,21 with a lack of
consensus on the level and rate of TFPI release.
More recent studies suggest that TFPIβ, an isoform of
TFPI, is present in endothelial cells.19,20,28-32 Although
not extensively studied, TFPIβ is not heparin-
releasable but, rather, is GPI anchored and probably
acts as a direct vessel wall anticoagulant. Therefore,
the aims of this study were to (1) validate the conditions
required to demonstrate the heparin-dependent
release of TFPI from endothelial cells, (2) determine
the effect of PLC on heparin-releasable TFPI in
endothelial cells, and (3) evaluate the effect of
heparin on GPI-anchored TFPI in endothelial cells.
A HUVEC model was used in this study because
collection of the cord is noninvasive to the donor,
isolation of cells is performed by well-defined meth-
ods, and the cells have physical and biochemical
characteristics that are comparable with endothelial
cells from other sites of the body. Previous studies
have used the immortalized endothelial cell lines
EA.hy926 and ECV304 cells,33 with recent evidence
suggesting that the latter is not of endothelial ori-
gin.34,35 Variable sources of endothelial cells used to
study the in vitro release of TFPI may contribute to
the conflicting data in the literature.
In the present study, heparin-releasable TFPI
activity levels were not significantly increased using
1 U/mL or 10 U/mL of UFH or LMWH after 1 hour or
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Figure 5. Effect of low-molecular-weight heparin (LMWH) on the release of tissue factor pathway inhibitor (TFPI) from human
umbilical vein endothelial cells. Cells were stimulated with LMWH (diluted in Dulbecco Modified Eagle’s Medium plus
5% fetal calf serum) for (A) 1 hour or (B) 24 hours. Columns represent mean heparin-releasable TFPI activity (mU/mL),
and error bars show 1 standard deviation. **Represents a statistically significant result.
Figure 6. Tissue factor pathway inhibitor (TFPI) release from
human umbilical vein endothelial cells after treatment
with phospholipase C (PLC). Columns represent
mean glycosylphosphatidylinositol-lipid−anchored
TFPI activity (mU/mL), and error bars show 1 stan-
dard deviation. **Represents a statistically significant
result.
24 hours of incubation with HUVECs when either
heparin was diluted in DMEM (Figures 2 and 3).
These findings are similar to recent reports in that a
significant increase in TFPI levels after 1 hour of
incubation with heparin was not demonstrated.17,18
The effect of heparin diluted in DMEM con-
taining 5% FCS on the release of heparin-releasable
TFPI from HUVECs was then investigated. A statis-
tically significant increase in heparin-releasable
TFPI activity with both UFH (P < .001) and LMWH
(P < .05) at 1 hour was demonstrated. No statisti-
cally significant increase in heparin-releasable TFPI
activity was observed at 24 hours. Of interest was
that the profile of TFPI release at 1 hour using the
different heparins varied. Maximum TFPI release
was achieved at a concentration of 1 U/mL when
UFH was used (Figure 4A) but 10 U/mL when
LMWH was used (Figure 5A). This suggests that at
the same concentration, UFH is more effective than
LMWH at inducing the in vitro release of TFPI.
These findings agree with those of Li et al15 and sug-
gest that a therapeutic dose of UFH (approximately
0.2-2 U/mL) induces maximum TFPI release from
endothelial cells and depletes storage pools, whereas
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Figure 8. Effect of phospholipase C (PLC) on the low-molecular-weight heparin (LMWH)-dependent release of tissue factor pathway
inhibitor (TFPI) from human umbilical vein endothelial cells. Cells were treated with PLC and then stimulated with LMWH
(diluted in Dulbecco Modified Eagle’s Medium plus 5% fetal calf serum) for (A) 1 hour or (B) 24 hours. Columns represent
mean heparin-releasable TFPI activity (mU/mL), and error bars show 1 standard deviation. TBS = Tris-buffered saline.
Figure 7. Effect of phospholipase C (PLC) on the unfractionated heparin (UFH)−dependent release of tissue factor pathway
inhibitor (TFPI) from human umbilical vein endothelial cells. Cells were treated with PLC then stimulated with UFH
(diluted in Dulbecco Modified Eagle’s Medium plus 5% fetal calf serum) for (A) 1 hour or (B) 24 hours. Columns represent
mean heparin-releasable TFPI activity (mU/mL), and error bars show 1 standard deviation. TBS = Tris-buffered saline.
LMWH does not. These results thus offer further
insight into the findings of Hansen et al36 and Bendz
et al,37 who reported that UFH⎯but not LMWH⎯
depletes heparin-releasable TFPI in vivo.
Our data clearly demonstrate that serum is
required for the heparin-mediated release of TFPI
from HUVECs. Previous studies that have reported
a heparin-mediated release of TFPI from HUVECs
used serum,13,15,17 although the significance of this
was not discussed. Additional supporting evidence
for our findings that serum is required for the
heparin-dependent release of TFPI is provided by
Perez-Ruiz et al,18 who demonstrated minimal TFPI
release from HUVECs when using serum-free
media. It is interesting to speculate what specific
serum component(s) might be required for the
heparin-dependent release of TFPI from HUVECs.
It has recently been demonstrated that basic fibro-
blast growth factor, in conjunction with heparin,
releases TFPI from smooth muscle cells.38 Neither
of those components by themselves had any effect
on TFPI levels, however. It could be that basic
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Figure 9. Effect of unfractionated heparin (UFH) on the phospholipase C (PLC)−dependent release of tissue factor pathway
inhibitor (TFPI) from human umbilical vein endothelial cells. Cells were exposed to UFH (diluted in Dulbecco Modified
Eagle’s Medium plus 5% fetal calf serum) for (A) 1 hour or (B) 24 hours and then were treated with PLC. Columns rep-
resent mean glycosylphosphatidylinositol-lipid-anchored TFPI activity (mU/mL), and error bars show 1 standard deviation.
Figure 10. Effect of low-molecular-weight heparin (LMWH) on the phospholipase C (PLC)−dependent release of tissue factor
pathway inhibitor (TFPI) from human umbilical vein endothelial cells. Cells were exposed to LMWH (diluted in
Dulbecco Modified Eagle’s Medium plus 5% fetal calf serum) for (A) 1 hour or (B) 24 hours and then were treated
with PLC. Columns represent mean glycosylphosphatidylinositol-lipid-anchored TFPI activity (mU/mL), and error bars
show 1 standard deviation.
fibroblast growth factor or a related protein is an
additional requirement for the heparin-mediated
release of TFPI from HUVECs.
Treatment of HUVECs with PLC was used to
investigate the release of GPI-anchored TFPI. An
approximate 20-fold increase in TFPI activity in
HUVEC supernatants was observed after treatment
with PLC (Figure 6), confirming that a portion of
endothelial cell surface−associated TFPI is GPI
anchored.19,20,29 The amount of TFPI released by PLC
in this study is significantly greater than that by Lupu
et al29 (1997) and is probably accounted for by the
higher concentration of PLC used in our study.
Sequential treatment of HUVECs with heparin
and PLC was performed to determine if PLC
affected heparin-releasable TFPI and if heparin
influenced PLC-releasable TFPI. Treatment of
HUVECs with PLC, then with heparin, for 1 or 24
hours resulted in no statistically significant difference
in the amount of heparin-releasable TFPI compared
with the control (Figures 7 and 8), suggesting that
PLC has no effect on heparin-releasable TFPI. This
contrasts with the 2002 findings of Mast et al,19 who
observed an approximate 4-fold increase in the
amount of heparin-releasable TFPI in minced pla-
cental samples after pretreatment with PLC. These
results may be due to cells other than that of endo-
thelial origin, for example, syncytiotrophoblasts,
cytotrophoblasts, and extravillous trophoblasts of
the placenta, which have been demonstrated to pro-
duce TFPI.39 Therefore, the differences observed
between the studies are likely due to the different
experimental models.
Although no statistically significant difference in
the levels of GPI-anchored TFPI after treatment of
HUVECs with heparin (UFH or LMWH for 1 or 24
hours) then PLC (Figures 9 and 10) was evident, 2
clear trends were observed. After a 1-hour incuba-
tion with either heparin, a dose-dependent increase
in GPI-anchored TFPI was observed (Figures 9 and
10A). Compared with the control, the increase was
12% and 19% for 1 and 10 U/mL UFH and 7% and
26% for 1 and 10 U/mL LMWH. These results may
be due to TFPIα binding to a GPI-anchored protein
on the cell surface (eg, glypican-3),40 after the initial
release by heparin. After treatment with PLC,
TFPIα would then be cleaved from the cell surface,
accounting for the heparin dose-dependent increase
in GPI-anchored TFPI.
After 24 hours’ incubation with either heparin
preparation, a decrease in GPI-anchored TFPI was
observed (Figures 9 and 10B). At concentrations of
1 and 10 U/mL, the respective decreases compared
with the control were 25% and 15% with UFH and
35% and 30% with LMWH. The reason for this
decrease is not known, although it may be that bind-
ing of TFPIα to a putative GPI-anchored protein
promotes its internalization and degradation, result-
ing in the lesser amount of GPI-anchored TFPI. It
has also been suggested that a small pool of TFPIα
exists on the cell surface that is resistant to heparin
but is released after PLC treatment.20 However, the
heparin incubation period used was just 20 minutes.
A longer period of time may be required for heparin
to dissociate TFPIα from the GPI-anchored pro-
tein to which it binds, which would account for
the decrease in GPI-anchored TFPI observed after
24 hours’ heparin treatment.
Conclusion
This study demonstrated that serum is a require-
ment for the heparin-dependent release of TFPI
from HUVECs. Furthermore, a trend was observed
where a 1-hour pretreatment of HUVECs with
heparin dose dependently increased PLC-releasable
TFPI, whereas a 24-hour pretreatment resulted in a
dose-dependent decrease. Further studies are
required to elucidate the exact serum components
required for the heparin-dependent release of TFPI
and to confirm the observed effect of heparin on
GPI-anchored TFPI.
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